ASHM provides leadership in health workforce and research-based policy development and supports the efforts of others relating to policy and advocacy in the sector. This work includes the development of Position Statements, in consultation with our members. If you have policy issues which you think should be brought to ASHM's attention, please email ashm@ashm.org.au.
ASHM is a member of the National Blood Borne Viruses and Sexually Transmissible Infections Standing Committee (BBVSS) and contributes to the development of national , state and territory sexual health and BBV strategies and implementation/action plans.
|
Third National Hepatitis B Strategy 2018-2020 |
|
|
Endorsement of Hepatitis B management during immunosuppression for haematological and solid-organ malignancies: an Australian Consensus Statement 2018 |
|
|
Hepatitis B and Immigration – a template to support clinicians who have patients with chronic hepatitis B applying for a permanent visa |
|
|
Recommendation to update the Guidelines for Preventive Activities in General Practice (Red Book) to include hepatitis B |
|
|
Submission to CDNA on National Guidelines on Infected Health Care Workers |
|
|
Successful submission to PBAC to allow HBV s100 GPs to initiate CHB treatment |
|
|
Position statement on Nurse Practitioner Prescribing for Section 100 Medications for the treatment of HIV and Hepatitis B and Section 85 Medications for Hepatitis C in Australia |
|
|
Submission to Australian Health Practitioner Regulation Agency (AHPRA) on National Guidelines on Infected Health Care Workers |
|
|
Endorsement of Australasian Hepatology Association (AHA) Practice Standards for the Hepatology Nurse |
|
|
Contribution to National guide to a preventive health assessment for Aboriginal and Torres Strait Islander people |
|
|
Contribution to Protocol Advisory Sub-Committee of MSAC on protocol application for the use of Transient Elastography for Viral Hepatitis |
|
|
Letter against the introduction of mandatory BBV testing in NSW, QLD and SA |
|
|
Submission to CDNA on National Guidelines on Infected Health Care Workers |
|
|
Submission to TGA Review of Medicines and Medical Devices Regulation |
|
|
Advocacy to remove liver biopsy as a requirement prior to treatment |
|
|
Advocacy on hepatitis B prescribing and dispensing |
|
|
Development of the Auckland Statement on viral hepatitis |
|
|
Contribution to MSAC application for the use of Transient Elastography for Viral Hepatitis |
|
Fifth National Hepatitis C Strategy 2018-2020 |
|
|
Recommendation to update the Guidelines for Preventive Activities in General Practice (Red Book) to include hepatitis C |
|
|
Submission on simplification of HCV DAA PBS listing |
|
|
Submission to CDNA on National Guidelines on Infected Health Care Workers |
|
|
Submission to PHARMAC on pangenotypic medications for HCV |
|
|
Addition of nurse practitioner experienced in the treatment of hepatitis C to the treatment criteria in the PBS listing for HCV DAAs |
|
|
Addition of medical practitioner or an authorised nurse practitioner experienced in the treatment of chronic hepatitis C to the treatment criteria in the PBS listing for HCV DAAs |
|
|
Position statement affirming efficacy of Direct Acting Antiviral therapy for hepatitis C |
|
|
Position statement on Nurse Practitioner Prescribing for Section 100 Medications for the treatment of HIV and Hepatitis B and Section 85 Medications for Hepatitis C in Australia |
|
|
Letter of support for listing of pangenotypic HCV DAA treatments on the PBS |
|
|
Submission to PBAC on broad prescriber eligibility for HCV DAAs prior to PBS listing |
|
|
Submission and Presentation at Senate Inquiry into Hepatitis C |
|
|
Joint submission with Hepatitis Foundation New Zealand to PHARMAC on impacts of Hepatitis C treatment in New Zealand |
|
|
Submission to Australian Health Practitioner Regulation Agency (AHPRA) on National Guidelines on Infected Health Care Workers |
|
|
Endorsement of Australasian Hepatology Association (AHA) Practice Standards for the Hepatology Nurse |
|
|
Contribution to National guide to a preventive health assessment for Aboriginal and Torres Strait Islander people |
|
|
Contribution to Protocol Advisory Sub-Committee of MSAC on protocol application for the use of Transient Elastography for Viral Hepatitis |
|
|
Letter against the introduction of mandatory BBV testing in NSW, QLD and SA |
|
|
Position statement and guidance for clinicians on importation of generic DAAs |
|
|
Submission to CDNA on National Guidelines on Infected Health Care Workers |
|
|
Submission to TGA Review of Medicines and Medical Devices Regulation |
|
|
Development of the Auckland Statement on viral hepatitis |
|
|
Contribution to MSAC application for the use of Transient Elastography for Viral Hepatitis |
|
|
Submission to Red Cross review of blood donations from people who inject drugs |
|
Eighth National HIV Strategy 2018-2020 |
|
|
Undetectable=Untransmittable (U=U): a guide for clinicians |
|
|
Submission to CDNA on National Guidelines on Infected Health Care Workers |
|
|
Letter against the introduction of mandatory BBV testing in NSW, QLD and SA |
|
|
Contribution to PBAC submission for PrEP application |
|
|
Position statement on Nurse Practitioner Prescribing for Section 100 Medications for the treatment of HIV and Hepatitis B and Section 85 Medications for Hepatitis C in Australia |
|
|
Letter against mandatory BBV testing to Attorney General, Legal Aid Commission and Police Union |
|
|
Advocacy with UNAIDS on HIV and immigration |
|
|
Submission to Australian Health Practitioner Regulation Agency (AHPRA) on National Guidelines on Infected Health Care Workers |
|
|
Contribution to National guide to a preventive health assessment for Aboriginal and Torres Strait Islander people |
|
|
Submission to TGA on HIV POCT |
|
|
Submission to CDNA on National Guidelines on Infected Health Care Workers |
|
|
Submission to TGA Review of Medicines and Medical Devices Regulation |
|
|
Successful submission to PBAC to remove CD4+ count as part of treatment criteria for HIV |
|
Fourth National Sexually Transmissible Infections Strategy 2018-2020 |
|
|
Third National Sexually Transmissible Infections Strategy 2014-2017 |
|
|
Contribution to National guide to a preventive health assessment for Aboriginal and Torres Strait Islander people |
|
|
Second National Sexually Transmissible Infections Strategy 2010-2013 |
|
Fifth National Aboriginal and Torres Strait Islander Blood-Borne Viruses and Sexually Transmissible Infections Strategy 2018-2020 |
|
Contribution to National guide to a preventive health assessment for Aboriginal and Torres Strait Islander people |
|
Letter protesting defunding of 2 Spirits programs |
|
National Strategy feedback meeting |
|
Undetectable=Untransmittable (U=U): a guide for clinicians |
|
|
Statement refuting Cochrane Review on the efficacy of DAA therapy |
|
